About Galaxy Diagnostics
Galaxy Diagnostics is a company based in Durham (United States) founded in 2009. Galaxy Diagnostics has raised $12.76 million across 9 funding rounds from investors including HHS. Galaxy Diagnostics offers products and services including Bartonella Digital ePCR and Lyme Borrelia Direct Detect Nanotrap. Galaxy Diagnostics operates in a competitive market with competitors including Inflammatix, Karius, MeMed, Visby Medical and NeuMoDx, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Galaxy Diagnostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.76 M (USD)
in 9 rounds
-
Latest Funding Round
$3.02 M (USD), Series A
May 01, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Galaxy Diagnostics
Galaxy Diagnostics offers a comprehensive portfolio of products and services, including Bartonella Digital ePCR and Lyme Borrelia Direct Detect Nanotrap.
Detects Bartonella infections in blood samples using advanced PCR technology.
Identifies Lyme disease antigens in urine for accurate infection confirmation.
People of Galaxy Diagnostics
Unlock access to complete
Funding Insights of Galaxy Diagnostics
Galaxy Diagnostics has successfully raised a total of $12.76M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $3.02 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Galaxy Diagnostics
Galaxy Diagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Galaxy Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Galaxy Diagnostics
Investment portfolio details for Galaxy Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Galaxy Diagnostics
Detailed financials for Galaxy Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Galaxy Diagnostics Comparisons
Peer comparison for Galaxy Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Galaxy Diagnostics
Galaxy Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Karius, MeMed, Visby Medical and NeuMoDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
Detailed competitors of Galaxy Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Galaxy Diagnostics
Complete news archive for Galaxy Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Galaxy Diagnostics
Galaxy Diagnostics was founded in 2009.
Galaxy Diagnostics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Galaxy Diagnostics is a funded company, having raised a total of $12.76M across 9 funding rounds to date.
Galaxy Diagnostics is an infectious disease testing company founded by researchers at NC State University College of Veterinary Medicine. The company offers PCR tests to confirm Bartonella infection and other pathogens. Its product, the Bartonella ePCR test combines proprietary enrichment culture with compassionate PCR methods to provide a highly sensitive detection test for Bartonella spp. The company offers PCR tests to detect a broad range of species within each genus of Bartonella spp, Anaplasma spp, Ehrlichia spp, Rickettsia spp, and Babesia.
Galaxy Diagnostics's top competitors include Visby Medical, Inflammatix and MeMed.
Galaxy Diagnostics offers Bartonella Digital ePCR and Lyme Borrelia Direct Detect Nanotrap.
Galaxy Diagnostics has 1 investor. Key investors include HHS.